Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial

James, 2012, Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer, N Engl J Med, 366, 1477, 10.1056/NEJMoa1106106 Vale, 2005, Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration, Eur Urol, 48, 202, 10.1016/j.eururo.2005.04.006 Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148 Yin, 2016, Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis, Oncologist, 21, 708, 10.1634/theoncologist.2015-0440 Bernardini, 2001, Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer, J Urol, 166, 1275, 10.1016/S0022-5347(05)65752-7 Bochner, 1995, Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis, J Natl Cancer Inst, 87, 1603, 10.1093/jnci/87.21.1603 Pruthi, 2010, A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results, BJU Int, 106, 349, 10.1111/j.1464-410X.2009.09101.x Roskoski, 2020, The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder, Pharmacol Res, 151, 10.1016/j.phrs.2019.104567 Galsky, 2013, Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer, Clin Genitourin Cancer, 11, 175, 10.1016/j.clgc.2012.10.001 Necchi, 2018, Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: an open-label, single-arm, single-center, phase 2 study, Urol Oncol, 36, 8.e1, 10.1016/j.urolonc.2017.08.020 Forster, 2018, A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3), Lung Cancer, 120, 27, 10.1016/j.lungcan.2018.03.007 Hanna, 2016, Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial, Lung Cancer, 102, 65, 10.1016/j.lungcan.2016.10.011 Reck, 2014, Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial, Lancet Oncol, 15, 143, 10.1016/S1470-2045(13)70586-2 Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron J, 16, 31, 10.1159/000180580 Catto, 2021, Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study, J Clin Oncol, 39, 202, 10.1200/JCO.20.01665 Jefferies, 2018, Open radical cystectomy in England: the current standard of care—an analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit and Hospital Episodes Statistics (HES) data, BJU Int, 121, 880, 10.1111/bju.14143 Griffiths, 2011, International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial, J Clin Oncol, 29, 2171, 10.1200/JCO.2010.32.3139 Jung, 2008, Randomized phase II trials with a prospective control, Stat Med, 27, 568, 10.1002/sim.2961 Rosenberg, 2021, Randomized phase III trial of gemcitabine and cisplatin with bevacizumab or placebo in patients with advanced urothelial carcinoma: results of CALGB 90601 (Alliance), J Clin Oncol, 39, 2486, 10.1200/JCO.21.00286 Balar, 2013, Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer, J Clin Oncol, 31, 724, 10.1200/JCO.2012.42.5215 Hahn, 2011, Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75, J Clin Oncol, 29, 1525, 10.1200/JCO.2010.31.6067 Petrylak, 2017, Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial, Lancet, 390, 2266, 10.1016/S0140-6736(17)32365-6 Petrylak, 2020, Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial, Lancet Oncol, 21, 105, 10.1016/S1470-2045(19)30668-0 Kato, 2021, Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts, Br J Cancer, 124, 914, 10.1038/s41416-020-01201-z Petrelli, 2014, Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis, Eur Urol, 65, 350, 10.1016/j.eururo.2013.06.049